Clinical trials: Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D)
Diarrhea Predominant Irritable Bowel Syndrome
Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS
This study is being conducted to see if serum-derived bovine immunoglobulin/protein isolate (SBI) is safe and well tolerated in pediatric patients with IBS-D.
- Trial name
- NCT02358694
- Testing
- Serum-Derived Bovine Immunoglobulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Connecticut Children's Medical Center
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
IBS-D and Functional Dyspepsia
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
Primary Objective: To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01268618
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sprim Advanced Life Sciences
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Efficacy of Rifaximin With NAC in IBS-D
The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D).
- Trial name
- NCT06727422
- Testing
- rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Mark Pimentel, MD
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Diarrhea-Predominant Irritable Bowel Syndrome
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The goal of this clinical trial is to test the efficacy and safety of the Chinese patent medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- NCT05687435
- Testing
- Changyanning tablet
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Mei Han
Irritable Bowel Syndrome
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome…
- Trial name
- NCT02328547
- Testing
- Fecal microbiota transplantation capsules
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Montefiore Medical Center
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome With Diarrhoea
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.
- Trial name
- MIBS (NCT01316718)
- Testing
- Mesalazine
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- University of Nottingham
Diarrhea-predominant Irritable Bowel Syndrome
Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The investigators will perform a multicenter, 2:1 randomized, double-blinded, placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed according to Rome III criteria and the IBS-QOL…
- Trial name
- AMIRA (NCT04095988)
- Testing
- Allogeneic microbiota reconstitution
- Where
- 2 sites in Germany
- Volunteers
- 42 people
- Sponsor
- University of Ulm
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Diarrhoea Predominant Irritable Bowel Syndrome
Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA
The study aims to evaluate the impact on quality of life and abdominal discomfort of GABA and Melissa food supplement administration in patients with diarrhea-predominant irritable bowel syndrome.
- Trial name
- NCT06755489
- Testing
- GABA
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- University of Pisa
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
IBS is a disorder of movement in the gut. People who have IBS may have diarrhea, constipation, or alternating bouts of both. IBS is not caused by injury or illness.
- Trial name
- NCT02431533
- Testing
- PX0612, Di-Calcium Phosphate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Pharmabiotix Inc
Irritable Bowel Syndrome, Colonic Diseases
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
- Trial name
- NCT00101725
- Testing
- crofelemer
- Where
- 29 sites in United States
- Volunteers
- 245 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc